Gemcitabine is ineffective in recurrent, preirradiated cervical cancer

Gynecol Oncol. 2000 Jul;78(1):76-7. doi: 10.1006/gyno.2000.5817.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Adult
  • Aged
  • Antimetabolites, Antineoplastic / pharmacology
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / pharmacology
  • Deoxycytidine / therapeutic use
  • Disease Progression
  • Disease-Free Survival
  • Female
  • Gemcitabine
  • Granulocyte Colony-Stimulating Factor / administration & dosage
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Treatment Outcome
  • Uterine Cervical Neoplasms / drug therapy*
  • Uterine Cervical Neoplasms / pathology

Substances

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Granulocyte Colony-Stimulating Factor
  • Gemcitabine